Temel Kavramlar
Tedopi vaccine shows promise in treating lung cancer patients with secondary resistance to immunotherapy.
Özet
The article discusses the positive results of the phase 3 Atalante-1 trial for the Tedopi therapeutic vaccine in treating advanced non-small cell lung cancer patients with secondary resistance to immunotherapy. The vaccine targets five tumoral antigens and has shown benefits in improving overall survival rates and quality of life compared to standard chemotherapy. The study protocol, results, tolerability profile, and ongoing clinical development of Tedopi are detailed, highlighting the potential of this therapeutic vaccine in cancer treatment.
Key Highlights:
Positive results of the phase 3 Atalante-1 trial for the Tedopi therapeutic vaccine
Composition of Tedopi targeting five tumoral antigens for tumor-specific T-lymphocytes activation
Study protocol, patient selection, and primary endpoint of overall survival
Secondary resistance to immunotherapy and the impact on patient outcomes
Tolerability profile and quality of life improvements with Tedopi compared to chemotherapy
Ongoing clinical development of Tedopi in lung cancer, ovarian cancer, and pancreatic cancer trials
İstatistikler
The vaccine was effective for patients expressing the HLA-A2 gene, present in around half of the population.
Median OS was 11.1 months with Tedopi vs 7.5 months with docetaxel for patients with secondary resistance to immunotherapy.
The risk of death was reduced by 41% with the vaccine compared to chemotherapy.
Fewer serious adverse effects were reported with Tedopi (11.4%) than with docetaxel (35.1%).
Alıntılar
"The study needs confirmation from a further, larger phase 3 study in more than 300 patients with secondary resistance to immunotherapy to give us the statistical power we need to convince the regulatory authorities."
"The vaccine was well tolerated. It has benefits in terms of controlling disease symptoms and causes few side effects."